Breaking old paradigms: Th17 cells in autoimmune arthritis

Clinical Immunology

Volumn 132, Issue 3, 2009, Pages 295-304

  Peck, Ariana ^a   Mellins, Elizabeth D ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

IL 17; Rheumatoid arthritis; Th17

Indexed keywords

CYCLOOXYGENASE 2; CYTOKINE ANTIBODY; FLUINDOSTATIN; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 1BETA; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; RETINOIC ACID; SIMVASTATIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNE DISEASE; BONE EROSION; CARTILAGE DEGENERATION; CELL INFILTRATION; CHRONIC INFLAMMATION; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; HOMEOSTASIS; JOINT DESTRUCTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RHEUMATOID ARTHRITIS; SHORT SURVEY; SYNOVIUM; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL;

ANIMALS; ARTHRITIS, RHEUMATOID; BONE AND BONES; CARTILAGE; HUMANS; INTERLEUKIN-17; MODELS, IMMUNOLOGICAL; SYNOVITIS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 67651175878     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.03.522     Document Type: Short Survey

References (122)

1. Takayanagi H., Ogasawara K., Hida S., Chiba T., Murata S., Sato K., Takaoka A., Yokochi T., Oda H., Tanaka K., Nakamura K., and Taniguchi T. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408 (2000) 600-605
2. Huang W., O'Keefe R.J., and Schwarz E.M. Exposure to receptor-activator of NFkB ligand renders pre-osteoclasts resistant to IFN-gamma by inducing terminal differentiation. Arthritis Res. Ther. 5 (2002) R49-R59
3. Sato K., Suematsu A., Okamoto K., Yamaguchi A., Morishita Y., Kadono Y., Tanaka S., Kodama T., Akira S., Iwakura Y., Cua D.J., and Takayanagi H. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203 (2006) 2673-2682
4. Yang X.O., Pappu B.P., Nurieva R., Akimzhanov A., Kang H.S., Chung Y., Ma L., Shah B., Panopoulos A.D., Schluns K.S., Watowich S.S., Tian Q., Jetten A.M., and Dong C. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR-alpha and ROR-gamma. Immunity 28 (2008) 29-39
5. Mangan P., Harrington L., O'Quinn D., Helms W., Bullard D., Elson C., Hatton R., Wahl S., Schoeb T., and Weaver C. Transforming growth factor-beta induces development of the Th17 lineage. Nature 441 (2006) 231-234
6. Nistala K., and Wedderburn L.R. Th17 and regulatory T cells: rebalancing pro- and anti-inflammatory forces in autoimmune arthritis. Rheumatology (2009) kep028
7. Kotake S., Udagawa N., Hakoda M., Mogi M., Yano K., Tsuda E., Takahashi K., Furuya T., Ishiyama S., Kim K.-J., Saito S., Nishikawa T., Takahashi N., Togari A., Tomatsu T., Suda T., and Kamatani N. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum. 44 (2001) 1003-1012
8. Yamada H., Nakashima Y., Okazaki K., Mawatari T., Fukushi J.I., Kaibara N., Hori A., Iwamoto Y., and Yoshikai Y. Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis. Ann. Rheum. Dis. 67 (2008) 1299-1304
9. Kotake S., Nanke Y., Mogi M., Kawamoto M., Furuya T., Yago T., Kobashigawa T., Togari A., and Kamatani N. IFN-gamma-producing human T cells directly induce osteoclastogenesis from human monocytes via the expression of RANKL. Eur. J. Immunol. 35 (2005) 3353-3363
10. Bourg V., PortalËs P., Fiorito S., Combe B., Jorgensen C., Sany J., and Clot J. Intracytoplasmic Th1 and Th2 cytokines in rheumatoid arthritis blood and synovial tissue. J. Autoimmun. 13 (1999) 415-422
11. Pang M., Martinez A.F., Jacobs J., Balkan W., and Troen B.R. RANK ligand and interferon gamma differentially regulate cathepsin gene expression in pre-osteoclastic cells. Biochem. Biophys. Res. Commun. 328 (2005) 756-763
12. Alla Amcheslavsky Z.B.-S. Interleukin (IL)-12 mediates the anti-osteoclastogenic activity of CpG-oligodeoxynucleotides. J. Cell. Physiol. 207 (2006) 244-250
13. Tunyogi-Csapo M., Kis-Toth K., Radacs M., Farkas B., Jacobs J.J., Finnegan A., Mikecz K., and Glant T.T. Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption. Arthritis Rheum. 58 (2008) 2397-2408
14. Nakashima T., and Takayanagi H. The dynamic interplay between osteoclasts and the immune system. Arch. Biochem. Biophys. 473 (2008) 166-171
15. Chen N.-J., Huang M.-W., and Hsieh S.-L. Enhanced secretion of IFN-gamma by activated Th1 cells occurs via reverse signaling through TNF-related activation-induced cytokine. J. Immunol. 166 (2001) 270-276
16. Jacob C.O., Holoshitz J., Van der Meide P., Strober S., and McDevitt H.O. Heterogeneous effects of IFN-gamma in adjuvant arthritis. J. Immunol. 142 (1989) 1500-1505
17. Boissier M.-C., Chiocchia G., Bessis N., Hajnal J., Garotta G., Nicoletti F., and Fournier C. Biphasic effect of interferon-gamma in murine collagen-induced arthritis. Eur. J. Immunol. 25 (1995) 1184-1190
18. Irmler I.M., Gajda M., and Brauer R. Exacerbation of antigen-induced arthritis in IFN-gamma-deficient mice as a result of unrestricted IL-17 response. J. Immunol. 179 (2007) 6228-6236
19. Chu C.Q., Song Z., Mayton L., Wu B., and Wooley P.H. IFNgamma deficient C57BL/6 (H-2b) mice develop collagen induced arthritis with predominant usage of T cell receptor Vbeta6 and Vbeta8 in arthritic joints. Ann. Rheum. Dis. 62 (2003) 983-990
20. Vermeire K., Heremans H., Vandeputte M., Huang S., Billiau A., and Matthys P. Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J. Immunol. 158 (1997) 5507-5513
21. Verhoef C.M., van Roon J.A., Vianen M.E., Bijlsma J.W., and Lafeber F.P. Interleukin 10 (IL-10), not IL-4 or interferon-gamma production, correlates with progression of joint destruction in rheumatoid arthritis. J. Rheumatol. 28 (2001) 1960-1966
22. Sattler A., Wagner U., Rossol M., Sieper J., Wu P., Krause A., Schmidt W.A., Radmer S., Kohler S., Romagnani C., and Thiel A. Cytokine-induced human IFN-gamma-secreting effector-memory Th cells in chronic autoimmune inflammation. Blood 113 (2009) 1948-1956
23. Chu C.-Q., Swart D., Alcorn D., Tocker J., and Elkon K.B. Interferon-gamma regulates susceptibility to collagen-induced arthritis through suppression of interleukin-17. Arthritis Rheum. 56 (2007) 1145-1151
24. Guedez Y.B., Whittington K.B., Clayton J.L., Joosten L.A.B., van de Loo F.A.J., van den Berg W.B., and Rosloniec E.F. Genetic ablation of interferon-gamma up-regulates interleukin-1 beta expression and enables the elicitation of collagen-induced arthritis in a nonsusceptible mouse strain. Arthritis Rheum. 44 (2001) 2413-2424
25. Myers L.K., Kang L.K., Postlethwaite A.E., Rosloniec E.F., Morham S.G., Shlopov B.V., Goorha S., and Ballou L.R. The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis. Arthritis Rheum. 43 (2000) 2687-2693
26. Wiekowski M.T., Leach M.W., Evans E.W., Sullivan L., Chen S.-C., Vassileva G., Bazan J.F., Gorman D.M., Kastelein R.A., Narula S., and Lira S.A. Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death. J. Immunol. 166 (2001) 7563-7570
27. Piccotti J.R., Li K., Chan S.Y., Ferrante J., Magram J., Eichwald E.J., and Bishop D.K. Alloantigen-reactive Th1 development in IL-12-deficient mice. J. Immunol. 160 (1998) 1132-1138
28. Murphy C.A., Langrish C.L., Chen Y., Blumenschein W., McClanahan T., Kastelein R.A., Sedgwick J.D., and Cua D.J. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198 (2003) 1951-1957
29. Ziolkowska M., Koc A., Luszczykiewicz G., Ksiezopolska-Pietrzak K., Klimczak E., Chwalinska-Sadowska H., and Maslinski W. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J. Immunol. 164 (2000) 2832-2838
30. Chabaud M., Durand J.M., Buchs N., Fossiez F., Page G., Frappart L., and Miossec P. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 42 (1999) 963-970
31. Kotake S., Udagawa N., Takahashi N., Matsuzaki K., Itoh K., Ishiyama S., Saito S., Inoue K., Kamatani N., Gillespie M.T., Martin T.J., and Suda T. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103 (1999) 1345-1352
32. Plater-Zyberk C., Joosten L.A.B., Helsen M.M.A., Koenders M.I., Baeuerle P.A., and van den Berg W.B. Combined blockade of GM-CSF and IL-17 pathways potently suppresses chronic destructive arthritis in a TNF-alpha independent mouse model. Ann. Rheum. Dis. (2008) ard.2007.085431
33. Koenders M.I., Kolls J.K., Oppers-Walgreen B., Van Den Bersselaar L., Joosten L.A.B., Schurr J.R., Schwarzenberger P., Van Den Berg W.B., and Lubberts E. Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis. Arthritis Rheum. 52 (2005) 3239-3247
34. Hirota K., Hashimoto M., Yoshitomi H., Tanaka S., Nomura T., Yamaguchi T., Iwakura Y., Sakaguchi N., and Sakaguchi S. T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J. Exp. Med. 204 (2007)
35. Nakae S., Nambu A., Sudo K., and Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 171 (2003) 6173-6177
36. Lubberts E., van den Bersselaar L., Oppers-Walgreen B., Schwarzenberger P., Coenen-de Roo C.J.J., Kolls J.K., Joosten L.A.B., and van den Berg W.B. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NFkB ligand/osteoprotegerin balance. J. Immunol. 170 (2003) 2655-2662
37. Lubberts E., Huang W., Schwarzenberger P., Schurr J., Peschon J., van den Berg W.B., and Kolls J.K. Requirement of local synovial IL-17 receptor signaling in the progression of chronic synovitis and bone erosion in arthritis. Arthritis Res. Ther. 6 (2004) 58
38. Afzali B., Lombardi G., Lechler R.I., and Lord G.M. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin. Exp. Immunol. 148 (2007) 32-46
39. Hwang S.-Y., Kim J.-Y., Kim K.-W., Park M.-K., Moon Y., Kim W.-U., and Kim H.-Y. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NFkB- and PI3-kinase/Akt-dependent pathways. Arthritis Res. Ther. 6 (2004) R120-R128
40. Agarwal S., Misra R., and Aggarwal A. Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases. J. Rheumatol. 35 (2008) 515-519
41. Bertazzolo N., Punzi L., Stefani M.P., Cesaro G., Pianon M., Finco B., and Todesco S. Interrelationships between interleukin (IL)-1, IL-6 and IL-8 in synovial fluid of various arthropathies. Inflamm. Res. 41 (1994) 90-92
42. Georganas C., Liu H., Perlman H., Hoffmann A., Thimmapaya B., and Pope R.M. Regulation of IL-6 and IL-8 expression in rheumatoid arthritis synovial fibroblasts: the dominant role for NFkB but not C/EBP-beta or c-Jun. J. Immunol. 165 (2000) 7199-7206
43. Stamp L.K., Cleland L.G., and James M.J. Upregulation of synoviocyte COX-2 through interactions with T lymphocytes: role of interleukin 17 and tumor necrosis factor-alpha. J. Rheumatol. 31 (2004) 1246-1254
44. Shinomiya S., Naraba H., Ueno A., Utsunomiya I., Maruyama T., Ohuchida S., Ushikubi F., Yuki K., Narumiya S., Sugimoto Y., Ichikawa A., and Oh-ishi S. Regulation of TNF-alpha and interleukin-10 production by prostaglandins I2 and E2: studies with prostaglandin receptor-deficient mice and prostaglandin E-receptor subtype-selective synthetic agonists. Biochem. Pharmacol. 61 (2001) 1153-1160
45. Strassmann G., Patil-Koota V., Finkelman F., Fong M., and Kambayashi T. Evidence for the involvement of interleukin 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E2. J. Exp. Med. 180 (1994) 2365-2370
46. Trebino C.E., Stock J.L., Gibbons C.P., Naiman B.M., Wachtmann T.S., Umland J.P., Pandher K., Lapointe J.-M., Saha S., Roach M.L., Carter D., Thomas N.A., Durtschi B.A., McNeish J.D., Hambor J.E., Jakobsson P.-J., Carty T.J., Perez J.R., and Audoly L.P. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 9044-9049
47. Sheibanie A.F., Khayrullina T., Safadi F.F., and Ganea D. Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/interleukin-17 axis. Arthritis Rheum. 56 (2007) 2608-2619
48. Khayrullina T., Yen J.-H., Jing H., and Ganea D. In vitro differentiation of dendritic cells in the presence of prostaglandin E2 alters the IL-12/IL-23 balance and promotes differentiation of Th17 cells. J. Immunol. 181 (2008) 721-735
49. Katz Y., Nadiv O., Rapoport M.J., and Loos M. IL-17 regulates gene expression and protein synthesis of the complement system, C3 and factor B, in skin fibroblasts. Clin. Exp. Immunol. 120 (2000) 22-29
50. Mollnes T.E., Lea T., Mellbye O.J., Pahle J., Grand O., and Harboe M. Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex. Arthritis Rheum. 29 (1986) 715-721
51. Katschke Jr. K.J., Helmy K.Y., Steffek M., Xi H., Yin J., Lee W.P., Gribling P., Barck K.H., Carano R.A.D., Taylor R.E., Rangell L., Diehl L., Hass P.E., Wiesmann C., and van Lookeren Campagne M. A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis. J. Exp. Med. 204 (2007) 1319-1325
52. Banda N.K., Thurman J.M., Kraus D., Wood A., Carroll M.C., Arend W.P., and Holers V.M. Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collagen-induced arthritis. J. Immunol. 177 (2006) 1904-1912
53. Kim H.R., Cho M.L., Kim K.W., Juhn J.Y., Hwang S.Y., Yoon C.H., Park S.H., Lee S.H., and Kim H.Y. Up-regulation of IL-23p19 expression in rheumatoid arthritis synovial fibroblasts by IL-17 through PI3-kinase-, NFkB- and p38 MAPK-dependent signalling pathways. Rheumatology 46 (2007) 57-64
54. Yamaguchi Y., Fujio K., Shoda H., Okamoto A., Tsuno N.H., Takahashi K., and Yamamoto K. IL-17B and IL-17C are associated with TNF-alpha production and contribute to the exacerbation of inflammatory arthritis. J. Immunol. 179 (2007) 7128-7136
55. Lai Kwan Lam Q., King Hung Ko O., Zheng B.J., and Lu L. Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 14993-14998
56. Pers J.O., Daridon C., Devauchelle V., Jousse S., Saraux A., Jamin C., and Youinou P. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann. N. Y. Acad. Sci. 1050 (2005) 34-39
57. Xiao Y., Motomura S., and Podack E.R. APRIL (TNFSF13) regulates collagen-induced arthritis, IL-17 production and Th2 response. Eur. J. Immunol. 38 (2008) 3450-3458
58. Ju J.-H., Cho M.-L., Jhun J.-Y., Park M.-J., Oh H.-J., Min S.-Y., Cho Y.-G., Hwang S.-Y., Kwok S.-K., Seo S.-H., Yoon C.-H., Park S.-H., and Kim H.-Y. Oral administration of type-II collagen suppresses IL-17-associated RANKL expression of CD4+ T cells in collagen-induced arthritis. Immunol. Lett. 117 (2008) 16-25
59. F. Maione, N. Pashalidis, N. Mascolo, N. Dufton, M. Perretti, F. D'Acquisto, Interleukin 17 sustains rather than induces inflammation. Biochemical Pharmacology In Press, Accepted Manuscript.
60. Wakisaka S., Suzuki N., Nagafuchi H., Takeba Y., Kaneko A., Asai T., and Sakane T. Characterization of tissue outgrowth developed in vitro in patients with rheumatoid arthritis: involvement of T cells in the development of tissue outgrowth. Int. Arch. Allergy Immunol. 121 (2000) 68-79
61. Ziolkowska M., Koe A., Luszczykiewicz G., Ksiezopolska-Pietrzak K., Klimczak E., Chwalinska-Sadowska H., and Maslinski W. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporine A-sensitive mechanism. J. Immunol. 164 (2000) 2832-2838
62. Cho M.L., Yoon C.H., Hwang S.Y., Park M.K., Min S.Y., Lee S.H., Park S.H., and Kim H.Y. Effector function of type II collagen-stimulated T cells from rheumatoid arthritis patients. Arthritis Rheum. (2006)
63. Ryu S., Lee J., and Kim S. IL-17 increased the production of vascular endothelial growth factor in rheumatoid arthritis synoviocytes. Clin. Rheumatol. 25 (2006) 16-20
64. Honorati M.C., Neri S., Cattini L., and Facchini A. Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts. Osteoarthritis Cartilage 14 (2006) 345-352
65. Ottonello L., Cutolo M., Frumento G., Arduino N., Bertolotto M., Mancini M., Sottofattori E., and Dallegri F. Synovial fluid from patients with rheumatoid arthritis inhibits neutrophil apoptosis: role of adenosine and proinflammatory cytokines. Rheumatology 41 (2002)
66. Tak P.P., Smeets T.J., Daha M.R., Kluin P.M., Meijers K.A., Brand R., Meinders A.E., and Breedveld F.C. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum. 40 (1997) 217-225
67. Lubberts E., Joosten L., Oppers B., van den Bersselaar L., Coenen-de Roo C., Kolls J., Schwarzenberger P., van de Loo F., and van den Berg W. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J. Immunol. 167 (2001) 1004-1013
68. Priebe G.P., Walsh R.L., Cederroth T.A., Kamei A., Coutinho-Sledge Y.S., Goldberg J.B., and Pier G.B. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa. J. Immunol. 181 (2008) 4965-4975
69. Tan W., Huang W., Zhong Q., and Schwarzenberger P. IL-17 receptor knockout mice have enhanced myelotoxicity and impaired hemopoietic recovery following gamma irradiation. J. Immunol. 176 (2006) 6186-6193
70. Kehlen A., Thiele K., Riemann D., and Langer J. Expression, modulation and signaling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis. Clin. Exp. Immunol. 127 (2002) 539-546
71. Parsonage G., Filer A., Bik M., Hardie D., Lax S., Howlett K., Church L.D., Raza K., Wong S.-H., Trebilcock E., Scheel-Toellner D., Salmon M., Lord J.M., and Buckley C.D. Prolonged, granulocyte-macrophage colony-stimulating factor-dependent, neutrophil survival following rheumatoid synovial fibroblast activation by IL-17 and TNFalpha. Arthritis Res. Ther. 10 (2008) R47
72. Cho M.L., Jung Y.O., Kim K.W., Park M.K., Oh H.J., Ju J.H., Cho Y.G., Min J.K., Kim S.I., Park S.H., and Kim H.Y. IL-17 induces the production of IL-16 in rheumatoid arthritis. Exp. Mol. Med. 40 (2008) 237-245
73. Middel P., Reich K., Polzien F., Blaschke V., Hemmerlein B., Herms J., Korabiowska M., and Radzun H.J. Interleukin 16 expression and phenotype of interleukin 16 producing cells in Crohn's disease. Gut 49 (2001) 795-803
74. Numasaki M., Lotze M.T., and Sasaki H. Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts. Immunol. Lett. 93 (2004) 39-43
75. Nishiura H., Tanaka J., Takeya M., Tsukano M., Kambara T., and Imamura T. IL-8/NAP-1 is the major T-cell chemoattractant in synovial tissues of rheumatoid arthritis. Clin. Immunol. Immunopathol. 80 (1996) 179-184
76. Harada S., Yamamura M., Okamoto H., Morita Y., Kawashima M., Aita T., and Makino H. Production of interleukin-7 and interleukin-15 by fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum. 42 (1999) 1508-1516
77. Hirota K., Yoshitomi H., Hashimoto M., Maeda S., Teradaira S., Sugimoto N., Yamaguchi T., Nomura T., Ito H., Nakamura T., Sakaguchi N., and Sakaguchi S. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J. Exp. Med. (2007) 2803-2812
78. Goldring S. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology 42 (2003)
79. Cai L., Yin J., Starovasnik M., Hogue D., Hillan K., Mort J., and Filvarorff E. Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo. Cytokine 16 (2001) 10-21
80. Lubberts E., Joosten L.A., van de Loo F.A., van den Gersselaar L.A., and van den Berg W.B. Reduction of interleukin-17-induced inhibition of chondrocyte proteoglycan synthesis in intact murine articular cartilage by interleukin-4. Arthritis Rheum 43 (2000) 1300-1306
81. Pacquelet S., Presle N., Boileau C., Dumond H.l.n., Netter P., Martel-Pelletier J., Pelletier J.-P., Terlain B., and Jouzeau J.-Y. Interleukin 17, a nitric oxide-producing cytokine with a peroxynitrite-independent inhibitory effect on proteoglycan synthesis. J. Rheumatol. 29 (2002) 2602-2610
82. Chabaud M., Fossiez F., Taupin J.-L., and Miossec P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J. Immunol. 161 (1998) 409-414
83. Van de Loo F.A.J., Arntz O.J., and Van den Berg W.B. Effect of interleukin 1 and leukaemia inhibitory factor on chondrocyte metabolism in articular cartilage from normal and interleukin-6-deficient mice: role of nitric oxide and IL-6 in the suppression of proteoglycan synthesis. Cytokine 9 (1997) 453-462
84. Cai L., Suboc P., Hogue D.A., Fei D.T., and Filvaroff E.H. Interleukin 17 induced nitric oxide suppresses matrix synthesis and protects cartilage from matrix breakdown. J. Rheumatol. 29 (2002) 1725-1736
85. Lubberts E., Joosten L.A., Chabaud M., van Den Bersselaar L., Oppers B., Coenen-De Roo C.J., Richards C.D., Miossec P., and van Den Berg W.B. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J. Clin. Invest. 105 (2000) 1697-1710
86. Chabaud M., Lubberts E., Joosten L., van den Berg W., and Miossec P. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res. 3 (2001) 168-177
87. Shalom-Barak T., Quach J., and Lotz M. Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NFkB. J. Biol. Chem. 273 (1998) 27467-27473
88. Burrage P.S., Mix K.S., and Brinckerhoff C.E. Matrix metalloproteinases: role in arthritis. Front. Biosci. 11 (2006) 529-543
89. Sylvester J., Liacini A., Li W.Q., and Zafarullah M. Interleukin-17 signal transduction pathways implicated in inducing matrix metalloproteinase-3, -13 and aggrecanase-1 genes in articular chondrocytes. Cell. Signal. 16 (2004) 469-476
90. Jovanovic D.V., Martel-Pelletier J., Di B.J.A., Mineau F., Jolicoeur F.C., Benderdour M., and Pelletier J.-P. Stimulation of 92-kd gelatinase (matrix metalloproteinase 9) production by interleukin-17 in human monocyte/macrophages: a possible role in rheumatoid arthritis. Arthritis Rheum. 43 (2000) 1134-1144
91. van Lent P.L., Grevers L.C., Blom A.B., Arntz O.J., van de Loo F.A., van der Kraan P., Abdollahi-Roodsaz S., Srikrishna G., Freeze H., Sloetjes A., Nacken W., Vogl T., Roth J., and van der Berg W.B. Stimulation of chondrocyte-mediated cartilage destruction by S100A8 in experimental murine arthritis. Arthritis Rheum. 58 (2008) 3776-3787
92. Koshy P.J., Henderson N., Logan C., Life P.F., Cawston T.E., and Rowan A.D. Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann. Rheum. Dis. 61 (2002) 704-713
93. Chabaud M., Garnero P., Dayer J.M., Guerne P.A., Fossiez F., and Miossec P. Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine 12 (2000) 1092-1099
94. Väänänen H.K., and Laitala-Leinonen T. Osteoclast lineage and function. Arch. Biochem. Biophys. 473 (2008) 132-138
95. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., and Boyle W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
96. Kotake S., Sato K., Kim K.J., Takahashi N., Udagawa N., Nakamura I., Yamaguchi A., Kishimoto T., Suda T., and Kashiwazaki S. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J. Bone Miner. Res. 11 (1996) 88-95
97. Romas E., Gillespie M.T., and Martin T.J. Involvement of receptor activator of NFkB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 30 (2002) 340-346
98. Yago T., Nanke Y., Kawamoto M., Furuya T., Kobashigawa T., Kamatani N., and Kotake S. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res. Ther. 9 (2007) R96
99. Hashizume M., Hayakawa N., and Mihara M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatology 47 (2008) 1635-1640
100. Kobayashi K., Takahashi N., Jimi E., Udagawa N., Takami M., Kotake S., Nakagawa N., Kinosaki M., Yamaguchi K., Shima N., Yasuda H., Morinaga T., Higashio K., Martin T., and Suda T. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 191 (2000)
101. Tsukii K., Shima N., Mochizuki S., Yamaguchi K., Kinosaki M., Yano K., Shibata O., Udagawa N., Yasuda H., Suda T., and Higashio K. Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha, 25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. Biochem. Biophys. Res. Commun. 246 (1998) 337-341
102. Van Bezooijen R.L., Papapoulos S.E., and Löwik C.W. Effect of interleukin-17 on nitric oxide production and osteoclastic bone resorption: is there dependency on nuclear factor-kappaB and receptor activator of nuclear factor kappaB (RANK)/RANK ligand signaling?. Bone 28 (2001) 378-386
103. Imai K., Morikawa M., D'Armiento J., Matsumoto H., Komiya K., and Okada Y. Differential expression of WNTs and FRPs in the synovium of rheumatoid arthritis and osteoarthritis. Biochem. Biophys. Res. Commun. 345 (2006) 1615-1620
104. Feldmann M., and Maini R.N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Ann. Rev. Immunol. 19 (2001) 163-196
105. Kageyama Y., Takahashi M., Torikai E., Suzuki M., Ichikawa T., Nagafusa T., Koide Y., and Nagano A. Treatment with anti-TNF-alpha antibody infliximab reduces serum IL-15 levels in patients with rheumatoid arthritis. Clin. Rheumatol. 26 (2007) 505-509
106. Charles P., Elliott M.J., Davis D., Potter A., Kalden J.R., Antoni C., Breedveld F.C., Smolen J.S., Eberl G., deWoody K., Feldmann M., and Maini R.N. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J. Immunol. 163 (1999) 1521-1528
107. Notley C.A., Inglis J.J., Alzabin S., McCann F.E., McNamee K.E., and Williams R.O. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J. Exp. Med. 205 (2008) 2491-2497
108. Chiba K. A new orally active anti-rheumatic drug targets IL-15 and IL-17. Nihon Rinsho Meneki Gakkai Kaishi 30 (2007) 375-382
109. Xiao S., Jin H., Korn T., Liu S.M., Oukka M., Lim B., and Kuchroo K. Retinoic acid increases Foxp3+ regulatory t cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. J. Immunol. 181 (2008) 2277-2284
110. Elias K.M., Laurence A., Davidson T.S., Stephens G., Kanno Y., Shevach E.M., and O'Shea J.J. Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway. Blood 111 (2008) 1013-1020
111. Beehler B.C., Brinckerhoff C.E., and Ostrowski J. Selective retinoic acid receptor ligands for rheumatoid arthritis. Curr. Opin. Investig. Drugs 5 (2004) 1153-1157
112. Hermann F., Forster A., Chenevard R., Enseleit F., Hurlimann D., Corti R., Spieker L.E., Frey D., Hermann M., Riesen W., Neidhart M., Michel B.A., Hellermann J.P., Gay R.E., Luscher T.F., Gay S., Noll G., and Ruschitzka F. Simvastatin improves endothelial function in patients with rheumatoid arthritis. J. Am. Coll. Cardiol. 45 (2005) 461-464
113. Paraskevas K.I. Statin treatment for rheumatoid arthritis: a promising novel indication. Clin. Rheumatol. 27 (2008) 281-287
114. Nagashima T., Okazaki H., Yudoh K., Matsuno H., and Minota S. Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis. Arthritis Rheum. 54 (2006) 579-586
115. Yokota K., Miyoshi F., Miyazaki T., Sato K., Yoshida Y., Asanuma Y., Akiyama Y., and Mimura T. High concentration simvastatin induces apoptosis in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J. Rheumatol. 35 (2008) 193-200
116. Yokota K., Miyazaki T., Hirano M., Akiyama Y., and Mimura T. Simvastatin inhibits production of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-alpha in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J. Rheumatol. 33 (2006) 463-471
117. Lazzerini P.E., Lorenzini S., Selvi E., Capecchi P.L., Chindamo D., Bisogno S., Ghittoni R., Natale M.R., Caporali F., Giuntini S., Marcolongo R., Galeazzi M., and Laghi-Pasini F. Simvastatin inhibits cytokine production and nuclear factor-kB activation in interleukin 1 beta-stimulated synoviocytes from rheumatoid arthritis patients. Clin. Exp. Rheumatol. 25 (2007) 696-700
118. Zhang X., Jin J., Peng X., Ramgolam S., and Markovic-Plese S. Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J. Immunol. 180 (2008) 6988-6996
119. Zheng S.G., Wang J., and Horwitz D.A. Cutting edge: Foxp3+CD4+CD25+ regulatory T cells induced by IL-2 and TGF-beta are resistant to Th17 conversion by IL-6. J. Immunol. 180 (2008) 7112-7116
120. Doodes P.D., Cao Y., Hamel K.M., Wang Y., Farkas B., Iwakura Y., and Finnegan A. Development of proteoglycan-induced arthritis is independent of IL-17. J. Immunol. 181 (2008) 329-337
121. McGeachy M.J., Bak-Jensen K.S., Chen Y., Tato C.M., Blumenschein W., McClanahan T., and Cua D.J. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain TH-17 cell-mediated pathology. Nat. Immunol. 8 (2007) 1390-1397
122. Steinman L. A rush to judgment on Th17. J. Exp. Med. 205 (2008) 1517-1522